Harbor Investment Advisory LLC Reduces Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Harbor Investment Advisory LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,612 shares of the biopharmaceutical company’s stock after selling 52 shares during the period. Harbor Investment Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $2,573,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Mizuho Securities USA LLC raised its stake in shares of Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares during the period. Tri Locum Partners LP raised its stake in Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after acquiring an additional 8,949 shares during the period. Principal Financial Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. boosted its position in Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after purchasing an additional 3,231 shares during the period. Finally, Catalytic Wealth RIA LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $1,334,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on REGN shares. Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 14th. Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Wolfe Research began coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $681.58 on Tuesday. The stock’s 50-day moving average is $738.60 and its 200 day moving average is $948.80. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 1.61 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.